Familial hypobetalipoproteinemia due to a novel early stop mutation

被引:4
作者
Durrington, Paul. N. [1 ]
Charlton-Menys, Valentine [1 ]
Packard, Christopher J. [2 ]
Caslake, Muriel. J. [2 ]
Wang, Jian [3 ]
Bhatnagar, Deepak [1 ]
Scott, John [4 ]
Hegele, Robert A. [3 ]
机构
[1] Univ Manchester, Core Technol Facil, Div Cardiovasc & Endocrine Sci, Cardiovasc Res Grp, Manchester M13 9NT, Lancs, England
[2] Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[3] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada
[4] Univ Manchester, Fac Life Sci, Manchester M13 9NT, Lancs, England
关键词
Apolipoprotein B gene; Familial hypobetalipoproteinemia; HDL composition; Small-dense LDL;
D O I
10.1016/j.jacl.2008.08.446
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Familial hypobetalipoproteinemia (FHBL) is a co-dominant disorder associated with low circulating levels of low-density lipoprotein (LDL) cholesterol and apolipoprotein 13100 (ApoB). A proband was identified in whom the condition was due to an E110X mutation of APOB, creating a particularly early truncation of ApoB in the region of the molecule necessary for very-low-density lipoprotein (VLDL) assembly. The mutation was also associated with nonalcoholic tatty liver disease. OBJECTIVE: To assess the effect of the mutation on metabolism and the formation of VLDL and LDL subfractions. RESULTS: Both the proband and his son, who had the same mutation, had low LDL cholesterol and decreased ApoB, but an increased small-dense LDL level. Lipoprotein profiles were normal in the proband's sister and grandson. in whom the Mutation was absent. In the proband. there was a profoundly diminished rate of production of VLDL-2. VLDL-1 production, however. was relatively preserved and, because of its decreased catabolism, its pool size was increased. Direct formation of intermediate-density lipoprotein (IDL) and LDL was undetectable. Intermediate-density lipoprotein catabolism was greatly increased and its conversion to LDL was increased. The LDL produced was entirely small-dense LDL. High-density lipoprotein cholesterol levels were low, perhaps also related to the relative increase in VLDL-1, which is an avid acceptor of cholesteryl ester. CONCLUSIONS: This novel Mutation provides evidence to support the hypothesis that hepatic production of large VLDL-1 leads to the creation of small-dense LDL. (C) 2008 National Lipid Association. All rights reserved.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 35 条
[1]   Overproduction of large VLDL particles is driven by increased liver fat content in man [J].
Adiels, M ;
Taskinen, MR ;
Packard, C ;
Caslake, MJ ;
Soro-Paavonen, A ;
Westerbacka, J ;
Vehkavaara, S ;
Hakkinen, A ;
Olofsson, SO ;
Yki-Jarvinen, H ;
Borén, J .
DIABETOLOGIA, 2006, 49 (04) :755-765
[2]   Antisense apolipoprotein B therapy: where do we stand? [J].
Akdim, Fatima ;
Stroes, Erik S. G. ;
Kastelein, John J. P. .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (04) :397-400
[3]  
BLACKHART BD, 1986, J BIOL CHEM, V261, P5364
[4]   A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia [J].
Burnett, JR ;
Shan, J ;
Miskie, BA ;
Whitfield, AJ ;
Yuan, J ;
Tran, K ;
McKnight, CJ ;
Hegele, RA ;
Yao, ZM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (15) :13442-13452
[5]   Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia [J].
Caslake, MJ ;
Stewart, G ;
Day, SP ;
Daly, E ;
McTaggart, F ;
Chapman, MJ ;
Durrington, P ;
Laggner, P ;
Mackness, M ;
Pears, J ;
Packard, CJ .
ATHEROSCLEROSIS, 2003, 171 (02) :245-253
[6]   Intracellular translocation and stability of apolipoprotein B are inversely proportional to the length of the nascent polypeptide [J].
Cavallo, D ;
McLeod, RS ;
Rudy, D ;
Aiton, A ;
Yao, ZM ;
Adeli, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (50) :33397-33405
[7]   INVESTIGATION OF LIPID TRANSFER IN HUMAN-SERUM LEADING TO THE DEVELOPMENT OF AN ISOTOPIC METHOD FOR THE DETERMINATION OF ENDOGENOUS CHOLESTEROL ESTERIFICATION AND TRANSFER [J].
CHANNON, KM ;
CLEGG, RJ ;
BHATNAGAR, D ;
ISHOLA, M ;
ARROL, S ;
DURRINGTON, PN .
ATHEROSCLEROSIS, 1990, 80 (03) :217-226
[8]   Human cholesterol metabolism and therapeutic molecules [J].
Charlton-Menys, V. ;
Durrington, P. N. .
EXPERIMENTAL PHYSIOLOGY, 2008, 93 (01) :27-42
[9]   APOLIPOPROTEIN B-48 IS THE PRODUCT OF A MESSENGER-RNA WITH AN ORGAN-SPECIFIC IN-FRAME STOP CODON [J].
CHEN, SH ;
HABIB, G ;
YANG, CY ;
GU, ZW ;
LEE, BR ;
WENG, SA ;
SILBERMAN, SR ;
CAI, SJ ;
DESLYPERE, JP ;
ROSSENEU, M ;
GOTTO, AM ;
LI, WH ;
CHAN, L .
SCIENCE, 1987, 238 (4825) :363-366
[10]   An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis [J].
Crooke, RM ;
Graham, MJ ;
Lemonidis, KM ;
Whipple, CP ;
Koo, S ;
Perera, RJ .
JOURNAL OF LIPID RESEARCH, 2005, 46 (05) :872-884